Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Shares IssuedShares OutstandingShares Outstanding
Ratios

Ovid Therapeutics (OVID) Shares Outstanding (2016 - 2026)

Ovid Therapeutics filings provide 11 years of Shares Outstanding readings, the most recent being $167.3 million for Q1 2026.

  • Quarterly Shares Outstanding rose 135.22% to $167.3 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $167.3 million through Mar 2026, up 135.22% year-over-year, with the annual reading at $130.2 million for FY2025, 83.33% up from the prior year.
  • Shares Outstanding hit $167.3 million in Q1 2026 for Ovid Therapeutics, up from $130.2 million in the prior quarter.
  • Across five years, Shares Outstanding topped out at $167.3 million in Q1 2026 and bottomed at $123255.0 in Q1 2022.
  • Average Shares Outstanding over 5 years is $75.8 million, with a median of $70.8 million recorded in 2024.
  • The largest annual shift saw Shares Outstanding skyrocketed 5637250.8% in 2022 before it rose 0.19% in 2025.
  • Ovid Therapeutics' Shares Outstanding stood at $70.5 million in 2022, then grew by 0.32% to $70.7 million in 2023, then grew by 0.45% to $71.0 million in 2024, then soared by 83.33% to $130.2 million in 2025, then grew by 28.48% to $167.3 million in 2026.
  • Per Business Quant, the three most recent readings for OVID's Shares Outstanding are $167.3 million (Q1 2026), $130.2 million (Q4 2025), and $71.2 million (Q3 2025).